BALANCE: Binocularly Balanced Viewing Study

Sponsor
Moorfields Eye Hospital NHS Foundation Trust (Other)
Overall Status
Completed
CT.gov ID
NCT03754153
Collaborator
(none)
32
1
2
25.1
1.3

Study Details

Study Description

Brief Summary

Amblyopia is treated by glasses and patches or blurring eyedrops to the good eye. This works in about 70% of children, but parents and children strongly dislike these treatments which may carry on for years and involve frequent clinic visits. In this pilot trial, 66 children will receive, at random, either a Nintendo 3DSXL console with movies, or standard patching/blurring eye-drop treatment. The Investigators will monitor adverse events (double vision), change in the balance between the two eyes and in visual acuity over 16 weeks.

Condition or Disease Intervention/Treatment Phase
  • Device: Balanced Binocular Viewing (BBV)
  • Other: Standard Therapy - Occlusion (patching) or blurring (atropine)
N/A

Detailed Description

"Lazy eye" (amblyopia) is the commonest sight problem in children, affecting about one in 30 children. It is caused by a difference in spectacle prescription between the eyes and/or a squint (eye misalignment), with the brain ignoring one eye. Amblyopia is treated by glasses and patches or blurring eyedrops to the good eye. This works in about 70% of children, but parents and children strongly dislike these treatments which may carry on for years and involve frequent clinic visits.

The Investigators have developed an exciting new treatment: children watch customized movies for an hour a day on a hand-held 3D computer-game console. The Investigators blur the picture that the good eye sees to match it with what the weaker eye sees. They have tested this approach on 22 children, with an average improvement in vision by three lines on the test chart over 8 - 24 weeks, which may be faster than with standard treatment. Parents and children the Investigators have spoken with like both the idea of research in this area and the engaging nature of this device. The Investigators now need to assess how the new treatment compares with standard treatment, but first need to ensure that the new treatment is safe and that families will use it.

In this pilot trial, 66 children will receive, at random, either a Nintendo 3DSXL console with movies, or standard patching/blurring eye-drop treatment. The Investigators will monitor adverse events (double vision), change in the balance between the two eyes and in visual acuity over 16 weeks. Parents and children have helped develop this pilot - this involvement will be continued throughout the study. At study completion, children and parents will be involved in deciding how best to communicate the findings on hospital websites, in newsletters, at conferences and in medical journals.

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two-group parallel randomized controlled trialTwo-group parallel randomized controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
At each site, a masked orthoptist will carry out the study assessments.
Primary Purpose:
Treatment
Official Title:
Phase 2a Two-site Randomised Controlled Trial to Determine Safety of and Adherence With a New 'Binocularly Balanced Viewing' Treatment for Unilateral Amblyopia Compared With Standard Treatment in Children Age 3-8 Years
Actual Study Start Date :
Oct 28, 2019
Actual Primary Completion Date :
Dec 1, 2021
Actual Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Balanced Binocular Viewing (BBV)

The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.

Device: Balanced Binocular Viewing (BBV)
The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).

Active Comparator: Standard Therapy - Occlusion (patching) or blurring (atropine)

The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.

Other: Standard Therapy - Occlusion (patching) or blurring (atropine)
The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies

Outcome Measures

Primary Outcome Measures

  1. The evaluation of safety of the experimental intervention [16 weeks from randomization]

    To measure changes in suppression/interocular balance (considered to precede double vision) at 16 weeks from baseline, using a novel test of interocular balance, a contrast-sensitivity test presented on a PC

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 8 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age between 3.0 and less than 8.0 years

  • unilateral anisometropic, strabismic or combined mechanism amblyopia

  • best-corrected crowded logMAR visual acuity (BCVA) in the amblyopic eye worse than 0.2logMar

  • best corrected visual acuity in the better seeing eye 0.2 or better

  • difference in best corrected visual acuity between the two eyes of 0.2 logMAR or more

  • adapted to spectacles with no improvement in acuity in affected eye for two consecutive visits

  • no previous treatment for amblyopia other than glasses

Exclusion Criteria:
  • ocular cause for reduced visual acuity

  • inability to co-operate with assessment tests

  • other developmental disorders or learning or neurological disability that would impact on adherence to treatment

  • photopic epilepsy

  • myopia with spherical equivalent of greater than -6.00DS

  • previous intraocular surgery

  • inability to perform a crowded letter logMAR visual acuity test using a clinical trials standard testing method (ATS-HOTV protocol), either by naming or by matching letters

Contacts and Locations

Locations

Site City State Country Postal Code
1 Moorfields Eye Hospital NHS Foundation Trust London United Kingdom EC1V 2PD

Sponsors and Collaborators

  • Moorfields Eye Hospital NHS Foundation Trust

Investigators

  • Principal Investigator: Annegret Dahlmann-Noor, Moorfields Eye Hospital NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Moorfields Eye Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT03754153
Other Study ID Numbers:
  • DALA1031
First Posted:
Nov 27, 2018
Last Update Posted:
Dec 23, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 23, 2021